SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form ARS - Annual Report to Security Holders:
SEC Accession No. 0001193125-24-100808
Filing Date
2024-04-18
Accepted
2024-04-18 16:19:00
Documents
1
Period of Report
2023-12-31
Effectiveness Date
2024-04-18

Document Format Files

Seq Description Document Type Size
1 ARS d823697dars.pdf ARS 1544247
  Complete submission text file 0001193125-24-100808.txt   2128213
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: ARS | Act: 34 | File No.: 001-39536 | Film No.: 24854529
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)